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TransplantationAbstract Background: Cytomegalovirus (CMV) infection is one of the most common and severe
infections during the post-transplantation period. It threatens the survival of patients and the func-
tion of the transplanted organ.
Aim of the study: To screen for CMV infection among solid organ transplantation patients using
monitoring of CMV phosphoprotein 65 (CMVpp65) antigenemia and to detect if CMV infection
and disease were associated with certain human leukocyte antigen (HLA)-A locus genotypes among
the studied group.
Subjects and methods: Thirty solid organ transplantation patients were included for post-
transplantation follow up for symptoms and signs suggestive of CMV disease upto one year. Reg-
ular screening for CMV infection was done through CMVpp65 antigenemia detection by the
immunofluorescence technique. In addition, HLA-A genotype was determined for all patients using
the line probe assay.
Results: The present study showed that 9 out of 30 patients (30%) were positive for CMVpp65
antigenemia. The detected HLA-A alleles were HLA-A*01(no. = 16), HLA-A*02(no. = 11),
HLA-A*11(no. = 5), HLA-A*19(no. = 1), HLA-A*24(no. = 4), HLA-A*29(no. = 1),
HLA-A*30(no. = 16), HLA-A*92(no. = 4). Among the studied cases, 40% showed HLA-A*
01–30 type. There was a significant difference (P= 0.05) among detected HLA types as regards
CMVpp65 antigenemia, with HLA-A*02_11 representing 33.3% of CMVpp65 positive patients
and HLA-A*01_30 representing 57.1% of CMVpp65 negative patients.
346 R. Khalifa et al.Conclusion: Certain HLA alleles may have either a protective or predisposing role in CMV reac-
tivation. Thus, HLA typing might be helpful in estimating the risk of CMV disease during the post-
transplantation period and designing individualized therapy as regards the choice between preemp-
tive and prophylactic CMV therapy.
 2015 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cytomegalovirus (CMV) infection is a major cause of morbid-
ity in recipients of solid organ and bone marrow transplants in
spite of significant advances resulting from preemptive therapy
and early diagnosis. Thus, it limits the effectiveness of organ
transplantation as a procedure for the treatment of end-stage
diseases [1].
The virus is generally known to cause both direct and indi-
rect effects on transplant graft function. While direct effects of
CMV are mostly visible, indirect effects are virtually not. It can
result in a significant long-term complication, such as acute
and chronic graft rejection, secondary opportunistic, or accel-
erated atherosclerosis that influences patients’ and graft sur-
vival [2].
The immunosuppressive therapy decreases the function of
cellular immunity, which is important in protection against
viruses from Herpesviridae, Polyomaviridae and Papillo-
maviridae families. These viruses do not disappear after the
acute primary infection, but latently remain in the infected
organism for a long period. From time to time the latent
viruses reactivate due to pro-inflammatory triggers. In the
case of immunosuppression, the suppressed cellular immunity
is not able to inactivate the hive of viruses and symptomatic
secondary infection develops. The primary viral infection
developed under immunosuppressed condition usually results
in more severe symptoms. In most cases the source of the
viruses is the graft-organ from a seropositive donor [3].
CMV is the most common virus pathogen in solid organ
transplant recipients (kidney, heart, liver, lung and pancreas)
during the first six months after transplantation. A solid
organ recipient may be infected either by the exogenous virus
or by reactivation of the latent virus if they were CMV pos-
itive pre-transplantation. Those at highest risk of symp-
tomatic CMV disease are CMV sero-negative patients who
receive organs from CMV seropositive donors, and CMV
seropositive patients on heavily immunosuppressive regimens
[4].
CMV may manifest as a non-specific illness characterized
by fever, mononucleosis, leucopenia and thrombocytopenia.
It may also manifest as a variety of clinical syndromes includ-
ing pneumonitis, hepatitis, encephalitis and focal gastrointesti-
nal disease. In addition, CMV infection causes morbidity in
organ recipients through indirect effects on their immune
response, and is associated with increased risk of allograft
injury and rejection, opportunistic infections and late onset
malignancies such as Epstein Barr virus lympho-proliferative
disease [5].
The occurrence of severe CMV infection in transplant
patients has decreased thanks to modern diagnostics and effec-
tive drug-therapy. The sustained viral effects may lead to dam-
age of parenchymal organs, especially of graft-organs. Thus, itis not enough to treat the CMV-disease, it is rather better to
avoid the infection and the viral reactivation. When introduc-
ing the preventive therapy, it is recommended to determine the
risk factors for CMV-infection and to choose the preventive
procedures according to their effectiveness [6].
A 3-month prophylaxis against CMV infection with valaci-
clovir has been reported to be safe and effective in kidney
transplant recipients. However, during prophylaxis, CMVpp65
antigenemia develops in some patients. This CMV infection
may be either asymptomatic or mildly symptomatic (without
fever). In kidney transplant recipients intensive monitoring
of CMVpp65 antigenemia and early treatment of CMV infec-
tion, namely preemptive therapy, has been reported to be a
safe alternative to prophylaxis [7].
In the high risk group, the average incidence of CMV dis-
ease was 20.5% for renal and liver transplant recipients receiv-
ing 90 days of valganciclovir prophylaxis during clinical trials.
There appears to be very few viral or immunological markers
that accurately predict the subset of patients who will develop
CMV disease after prophylaxis [8].
Genetic variability influences susceptibility to several dis-
eases. A widespread range of diseases have been linked with
different human leukocyte antigen (HLA) genotypes, like
ankylosing spondylitis, rheumatoid arthritis, celiac disease,
insulin-dependent diabetes mellitus, multiple sclerosis, tuber-
culosis, etc. In the last two decades, findings concerning the
association of CMV infection with HLA were reported. The
authors investigated 15 types of HLA systems; 3 of them
(HLA-Cw7, HLA-B16 and HLA-B55) were protective against
CMV disease. The others (HLA-A2, HLA-A24, HLA-A32,
HLA-B7 of donors, HLA-B52, HLA-Bw4, HLA-DR6,
HLA-DR11, HLA-DR15) increased the risk of the develop-
ment of CMV infection [9].
Major histocompatibility complex molecules are critical for
antigen uptake, processing and presentation. The association
of some HLA alleles with active CMV infection might be
due to differential presentation of CMV peptides by HLA
molecules or differential recognition by host CD8+ and
CD4+ T lymphocytes. A Japanese study suggests that the
deficient production of neutralizing antibodies against CMV
in certain HLA types may lead to the increased susceptibility.
Others suppose that distinct HLA types may enhance the pro-
duction of TNF-a giving rise to CMV end-organ diseases [10].
The CMVpp65 antigenemia test is an immunofluorescence-
based assay that utilizes an indirect immunofluorescence tech-
nique for identifying the CMVpp65 phosphoprotein of CMV
in peripheral blood leukocytes. The CMVpp65 assay is widely
used as the gold standard for monitoring CMV infections and
the response of CMV positive patients to antiviral treatment
[1].
To date, reports have suggested that the genetic mutation
of hosts and HLA genotypes might play an important role in
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sensitive measures for detecting CMV infection and HLA
genotypes has significantly reduced the incidence of CMV
infection and mortality of transplantation recipients [11].
2. Aim of the work
The present study aimed to screen for CMV infection among
solid organ transplantation patients using monitoring of
CMVpp65 antigenemia and to detect if CMV infection and
disease were associated with certain HLA-A genotypes among
the studied group.
3. Patients and methods
- Patients: The study included 30 solid organ transplantation
patients (6 liver transplantation and 24 renal transplanta-
tion patients) who underwent liver and renal transplanta-
tion at Ain Shams Center of Organ Transplantation
(ASCOT) of Ain Shams specialized hospital, and provided
a written consent to participate in the study during the per-
iod of December, 2012 till May, 2014.
- Methods: Patients were recruited one week post-
transplantation and they were subjected to:
 Full history taking and meticulous clinical examination for
any symptoms and signs suggestive of CMV disease as clin-
ical involvement of organ dysfunction such as diarrhea,
hepatitis, pancreatitis, retinitis, fever, and myocarditis.
Clinical follow up was performed weekly during the first
month, every other week during the next two months and
monthly up to one year. Patients’ serologic status was deter-
mined by detecting anti-CMV antibodies IgG (preopera-
tive) and IgM (on clinical suspicion of CMV disease).
 Detection of HLA genotype of A locus using sequence
specific polymerase chain reaction (PCR) and line probe
assay (LIPA).
 Screening for CMV infection by monitoring of CMVpp65
antigenemia using the immunoflourescence technique. This
was performed two weeks post-transplantation, three
months post-transplantation, by the end of the follow up
duration and on clinical suspicion of CMV disease.
3.1. Detection of HLA- A locus genotype
This was done using INNO-LiPA HLA-A Update Multiplex
PCR kit (Innogenetics, Belgium) in combination with the
INNO-LiPA HLA-A Update strips for the nucleic acid ampli-
fication of exon1, exon2, exon3 and exon4 of the HLA-A
locus. LIPA is based on the reverse-hybridization principle.
Amplified, biotinylated DNA material is chemically dena-
tured, and the single strands are hybridized with specific
oligonucleotide probes immobilized as parallel lines on
membrane-based strips. This process is followed by a stringent
wash step to remove any mismatched amplified material.
Thereafter, streptavidin conjugated with alkaline phosphatase
is added and bound to any biotinylated hybrid previously
formed. Incubation with a substrate solution containing a
chromogen results in a purple-brown precipitate. The reaction
is stopped by a wash step, and the reactivity pattern of the
probes is recorded [12].In brief, whole genomic DNA was extracted using High
Pure PCR Template Preparation kit (Roche, Germany) from
200 ll whole blood by adding 200 ll binding buffer and 40 ll
proteinase K with incubation at 70 C for 10 min, addition
of 100 ll isopropanol in a High Pure filter tube with centrifu-
gation for 1 min at 10,000 rpm, addition of 500 ll inhibitor
removal buffer followed by two washing steps in 500 ll wash
buffer and final elution at 70 C in 200 ll elution buffer by cen-
trifugation for 1 min at 10,000 rpm.
Amplification was performed in MicroAmp PCR tube,
GeneAmp PCR system 9700 thermal cycler and LiPA-Taq.
Five microliters of genomic DNA were added to 45 ll master
mix (10 ll amplification buffer containing an excess of
deoxynucleoside 50-triphosphates (dNTPs), 10 ll HLA-A mul-
tiplex biotinylated primers solution and 1.25 ll thermostable
LiPA-Taq DNA polymerase completed to 45 ll by autoclaved
distilled water). Cycling conditions were programed as follows;
initial denaturation at 96 C for 5 min followed by 35 cycles of
denaturation at 96 C for 30 s, annealing at 64 C for 50 s (5
cycles), annealing at 62 C for 50 s (5 cycles), annealing at
60 C for 50 s (10 cycles) and annealing at 55 C for 50 s (15
cycles) followed by extension at 72 C for 50 s for all cycles.
Final elongation was done at 72 C for 10 min.
The amplification products were subsequently hybridized
using 2 typing strips (INNO-LiPA HLA-A Update Plus strips
1 and 2) on which 44 sequence-specific probes and 2 control
lines are fixed. All reagents were brought to room temperature,
then, 10 ll of the alkaline denaturation solution was incubated
with 10 ll of the amplification product for 5 min at 25 C in
the developing trough. Two ml pre-warmed hybridization
solution (saline sodium phosphate EDTA buffer containing
0.5% sodium dodecyl sulfate) were added to the denatured
amplified product into each trough. Using a sterile forceps
strips 1 and 2 were placed in the troughs (one strip per trough).
The tray with the troughs was placed into a shaking water bath
for 30 min at 56 C.
After hybridization, the liquid was aspirated from the
trough with a pipette. Stringent wash was done 3 times by add-
ing 2 ml pre-warmed stringent wash solution with incubation
for 3 min at 56 C. Two ml of the conjugate working solution
(Streptavidin labeled with alkaline phosphatase in Tris buffer)
was added to each trough for 30 min while agitating the tray
on a shaker followed by twice wash step then addition of
2 ml of the substrate working solution (5-bromo-4-chloro-3-
indolyl phosphate p-toluidine salt and nitroblue tetrazolium
in dimethylformamide) with incubation for 30 min on a sha-
ker. Stop step was done by washing the strips twice in 2 ml dis-
tilled water on a shaker for 3 min. Finally, the strips were
removed by a forceps and left to dry before reading results
using the reading card included in the kit (Fig. 1a and b).
3.2. Screening for CMV infection by monitoring of CMVpp65
antigenemia using immunofluorescence technique
The CMV antigenemia test was performed for the detection of
CMVpp65 antigen in circulating peripheral blood leukocytes
(PBL) within 6 h of sample collection. This was done accord-
ing to Moses et al. [13]. Immunocytologic assay was performed
by the use of CMV BriteTM Turbo Kit (monoclonal antibody
(mouse, IgG1) against CMV lower matrix protein pp65) and
fluorescein isothiocyanate (FITC)-conjugated sheep anti-
Figure 2 Immun-flourescence image of CMVpp65 antigen in
PBL (as detected by fluorescent microscope during the present
study).
Table 1 Distribution of studied group as regard general data.
Variables No %
Gender
Male 20 66.7%
Female 10 33.3%
Age (range, mean ± SD) (18–56) 58.5 + 10 years
Figure 1 Developed INNO-LiPA HLA-A Update strip 1 (a) and
strip 2 (b).
348 R. Khalifa et al.mouse IgG antibody, supplied by IQ Products (Groningen,
Netherlands).
Cold lysing steps were done by adding 2 ml venous blood to
30 ml erythrocyte lysis solution diluted 1:10 in distilled water
for 5 min at 4 C followed by centrifugation for 2 min at
2500 rpm. Pellet was re-suspended in 1 ml phosphate buffer
saline (PBS) for cell count and cell number was adjusted to
2  106 cell/ml using a hemocytometer. Smears were prepared
by adding 100 ll of cell suspension onto glass slides followed
by centrifugation at 600 rpm for 4 min in cytospin. After over-
night air drying slides were dipped for 5 min in 1:5 diluted fix-
ative solution followed by washing in PBS then in 1:5 diluted
permeabilization solution for 1 min at room temperature fol-
lowed by washing in PBS.
After permeabilization, each slide was covered with 35 ll of
anti-CMVpp65 monoclonal antibody and incubated for20 min at 37 C in a humid chamber. After washing three times
in PBS, the slides were incubated with 35 ll of FITC conju-
gated anti-mouse immunoglobulin for 20 min at 37 C in a
humid chamber, followed by washing twice in fresh PBS.
Mounting medium and micro cover slides were applied. Con-
trol slides provided with the kit contained a negative control
spot and positive control spot. The positive control cells exhib-
ited homogenous yellow green poly-lobate nuclear fluorescence
staining while the negative control showed no yellow green
staining. The number of cells with homogenous green poly-
lobate nuclear fluorescence was scored under a fluorescent
microscope at 400 magnification. A positive assay result
was defined by the presence of at least 1 positively stained
leukocyte on the slide, and the result was expressed as the
number of CMVpp65-positive cells per 2  106 PBL (Fig. 2).
4. Definition of CMV infection and CMV disease
CMV infection was defined according to Ljungman et al. [14]
as the detection of CMV pp65 antigen in blood leukocytes in
the absence of clinical manifestations or organ function abnor-
malities. CMV disease was defined as the association of docu-
mented CMV infection with clinical symptoms, such as
unexplained fever and leukopenia (<4  109/L in two consec-
utive samples) and/or thrombocytopenia (<150  109/L).
5. Ethical considerations
The work has been carried out in accordance with The Code of
Ethics of the World Medical Association (Declaration of Hel-
sinki) for experiments in humans and the study was approved
by Ain Shams Center of Organ Transplantation ethics com-
mittee. The procedures of the study were discussed with partic-
ipating patients who provided informed consent for the
examination and tests included in the study.
6. Statistical methodology
Analysis of data was done by IBM computer using SPSS (sta-
tistical program for social science version 12) as follows:
 Description of quantitative variables as mean, SD and
range.
 Description of qualitative variables as number and
percentage.
 Chi-square test was used to compare qualitative variables
between groups.
 Unpaired t-test was used to compare quantitative variables,
in parametric data (SD < 50% mean).
 Mann–Whitney test was used instead of unpaired t-test in
non parametric data (SD > 50%mean).
Table 4 Distribution of the studied group as regards HLA
types.
Variables No %
HLA-A*01_24 2 6.7
HLA-A*01_30 12 40.0
HLA-A*01_92 2 6.7
HLA-A*02_11 4 13.3
HLA-A*02_19 1 3.3
HLA-A*02_24 1 3.3
HLA-A*02_29 1 3.3
HLA-A*02_30 2 6.7
HLA-A*02_92 2 6.7
HLA-A*11_30 1 3.3
HLA-A*19_24 1 3.3
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compare more than two groups as regards quantitative vari-
able (LSD= least significant difference).
 Spearman correlation co-efficient test was used to rank
variables versus each other positively or inversely.
 ROC curve (receiver operator characteristic curve was used
to find out the best cut off value, and validity of certain
variables).
 Sensitivity = true ve +/true +ve + false –ve= ability of
the test to detect +ve cases
 Specificity = true ve/trueve + false +ve= ability of
the test to exclude negative cases
 PPV(positive predictive value) = true+/true+ve + false
+ve=% of true +ve cases to all positiveTable 2 Detected HLA-A alleles, CMVpp65 antigenemia and
CMV disease among the studied group (no. = 30).
No HLA-A CMVpp65 CMV disease
1. HLA-A*01_30 VE VE
2. HLA-A*02_92 VE VE
3. HLA-A*02_11 +VE +VE
4. HLA-A*01_30 VE VE
5. HLA-A*02_30 +VE VE
6. HLA-A*01_30 VE VE
7. HLA-A*02_24 +VE VE
8. HLA-A*01_30 VE VE
9. HLA-A*19_30 VE VE
10. HLA-A*01_24 VE VE
11. HLA-A*01_30 VE VE
12. HLA-A*02_19 +VE VE
13. HLA-A*01_92 VE VE
14. HLA-A*01_30 VE VE
15. HLA-A*01_30 VE VE
16. HLA-A*02_11 +VE +VE
17. HLA-A*11_30 VE VE
18. HLA-A*19_24 VE VE
19. HLA-A*01_30 VE VE
20. HLA-A*02_29 +VE +VE
21. HLA-A*01_30 VE VE
22. HLA-A*01_92 VE VE
23. HLA-A*01_24 +VE VE
24. HLA-A*02_11 +VE VE
25. HLA-A*01_30 VE VE
26. HLA-A*02_30 VE VE
27. HLA-A*01_30 VE VE
28. HLA-A*02_11 VE VE
29. HLA-A*02_92 +VE +VE
30. HLA-A*01_30 VE VE
Table 3 Detected HLA-A alleles and CMVpp65 antigenemia
among studied group (no. = 30).
HLA-A Number CMVpp65 positive CMVpp65 negative
HLA-A*01 16 1 15
HLA-A*02 11 8 3
HLA-A*11 5 3 2
HLA-A*19 1 1 –
HLA-A*24 4 2 2
HLA-A*29 1 1 –
HLA-A*30 16 1 15
HLA-A*92 4 1 3
HLA-A*19_30 1 3.3
Total 30 100 NPV(negative predictive value) = true/trueve + false
ve=% of the true ve to all negative cases
P value > 0.05 insignificant
P< 0.05 significant
P< 0.01 highly significant
7. Results
Among the studied group, males were 66.7% of the studied
cases with an average age of 58.5 years (Table 1). All patients
(no. = 30) were seropositive (CMV IgG positive) with
seronegative donors. Nine patients (30%) were positive for
CMVpp65 antigenemia (Table 2). Among CMVpp65 antigen-
emia positive patients (no. = 9), 4 patients (44.4%) showed
symptoms of CMV disease in the form of fever (4 patients),
pneumonia (3 patients) and leukopenia (2 patients). Anti-
CMV IgM was positive in 2 out of 9 CMVpp65 positive
patients (22.2%). The number of CMVpp65-positive cells
was between 1 and 5 cells per 2  106 PBL among the 9
CMVpp65 positive samples.
The detected HLA-A alleles were HLA-A*01(no. = 16),
HLA-A*02(no. = 11), HLA-A*11(no. = 5), HLA-A*19(no.
= 1), HLA-A*24(no. = 4), HLA-A*29(no. = 1), HLA-A*30
(no. = 16) and HLA-A*92(no. = 4) (Table 3). HLA-A*1–30
type represented 40% of the studied cases (Table 4).
There was a significant difference (P= 0.05) among the
detected HLA types as regards CMVpp65 antigenemia, by
using chi-square test, where the majority of CMVpp65 positive
patients (33.3%) belonged to the HLA-A*02_11 type (com-
pared to 11.1% among each of the other HLA types) and
the majority of CMVpp65 negative patients (57.1%) belonged
to the HLA-A*01_30 type (Table 5). Also, by using the chi-
square test, there was a significant association between
CMVpp65 antigenemia and CMV disease (Table 6). No statis-
tically significant relation was found between HLA types ver-
sus CMV disease by using the chi-square test (Table 7).
8. Discussion
For patients who are immunosuppressed due to HIV infection
or solid organ or hematopoietic cell transplantation, CMV is a
potentially life-threatening complication. CMV has evolved
Table 5 Relation between HLA types versus CMVpp65 antigenemia.
Crosstab
CMVpp65 Total
ve +ve
HLA types HLA-A01_24 Count 1 1 2
% within CMVpp65 4.8% 11.1% 6.7%
HLA-A01_30 Count 12 0 12
% within CMVpp65 57.1% 0% 40.0%
HLA-A01_92 Count 2 0 2
% within CMVpp65 9.5% 0% 6.7%
HLA-A02_11 Count 1 3 4
% within CMVpp65 4.8% 33.3% 13.3%
HLA-A02_19 Count 0 1 1
% within CMVpp65 0% 11.1% 3.3%
HLA-A02_24 Count 0 1 1
% within CMVpp65 0% 11.1% 3.3%
HLA-A02_29 Count 0 1 1
% within CMVpp65 0% 11.1% 3.3%
HLA-A02_30 Count 1 1 2
% within CMVpp65 4.8% 11.1% 6.7%
HLA-A02_92 Count 1 1 2
% within CMVpp65 4.8% 11.1% 6.7%
HLA-A11_30 Count 1 0 1
% within CMVpp65 4.8% 0% 3.3%
HLA-A19_24 Count 1 0 1
% within CMVpp65 4.8% 0% 3.3%
HLA-A19_30 Count 1 0 1
% within CMVpp65 4.8% 0% 3.3%
Total Count 21 9 30
% within CMVpp65 100.0% 100.0% 100.0%
X2 = 19 P= 0.05(S)
Table 6 Relation between CMVpp65 antigenemia versus CMV disease.
CMV disease Total
ve +ve
CMVpp65 ve Count 21 0 21
% within CMV disease 80.8% 0% 70.0%
+ve Count 5 4 9
% within CMV disease 19.2% 100.0% 30.0%
Total Count 26 4 30
% within CMV disease 100.0% 100.0% 100.0%
X2 = 10.7 P= 0.002 (S)
350 R. Khalifa et al.escape mechanisms to evade both the innate natural killer
(NK) cells and adaptive (CD8+ T cells) immune responses.
Down-regulation of class I HLA expression and interference
with antigen presentation by virus-encoded genes diminishes
T-cell recognition but renders infected cells susceptible to
NK-cell lysis [15].
In immune-compromised patients, such as allogeneic bone
marrow transplant recipients, CMV infection can be a signifi-
cant complication. In these patients the recovery of CMV-
specific CD8+ cells response has been correlated with an
improved outcome from CMV disease. These observations
suggest an important role for the cellular immune response
in the control of CMV infection, and have encouraged studies
to identify the target antigens recognized by CMV-specific
CD8+ cells. One of the predominant viral antigens recognized
by CMV-specific CD8+ cells is the lower matrix 65-kDa phos-
phoprotein (pp65) [16].Risk factors for CMV reactivation include pre-
transplantation donor and recipient CMV serologic status
and post-transplantation development of acute graft-vs-host
disease (aGvHD). HLA allele type is an additional factor in
CMV infection [17].
The present study aimed to screen for CMV infection
among solid organ transplantation patients using monitoring
of CMVpp65 antigenemia and to detect if CMV infection
and disease were associated with certain HLA-A genotypes
among the studied group. The study included 30 solid organ
transplantation patients including 6 liver transplantation and
24 renal transplantation patients. Patients were subjected to
full history taking and meticulous clinical examination for
any symptoms and signs suggestive of CMV disease as clinical
involvement of organ dysfunctions such as diarrhea, with hep-
atitis, pancreatitis, retinitis, fever, and myocarditis, determin-
ing of patients’ serologic status by detection of anti-CMV
Table 7 Relation between HLA types versus CMV disease.
Crosstab
CMV disease Total
ve +ve
HLA types HLA-A01_24 Count 2 0 2
% within CMV disease 7.7% 0% 6.7%
HLA-A01_30 Count 12 0 12
% within CMV disease 46.2% 0% 40.0%
HLA-A01_92 Count 2 0 2
% within CMV disease 7.7% 0% 6.7%
HLA-A02_11 Count 2 2 4
% within CMV disease 7.7% 50.0% 13.3%
HLA-A02_19 Count 1 0 1
% within CMV disease 3.8% 0% 3.3%
HLA-A02_24 Count 1 0 1
% within CMV disease 3.8% 0% 3.3%
HLA-A02_29 Count 0 1 1
% within CMV disease .0% 25.0% 3.3%
HLA-A02_30 Count 2 0 2
% within CMV disease 7.7% 0% 6.7%
HLA-A02_92 Count 1 1 2
% within CMV disease 3.8% 25.0% 6.7%
HLA-A11_30 Count 1 0 1
% within CMV disease 3.8% 0% 3.3%
HLA-A19_24 Count 1 0 1
% within CMV disease 3.8% 0% 3.3%
HLA-A19_30 Count 1 0 1
% within CMV disease 3.8% 0% 3.3%
Total Count 26 4 30
% within CMV disease 100.0% 100.0% 100.0%
X2 = 17 P= 0.1 (NS)
Predictors for cytomegalovirus disease in solid organ transplant recipients 351antibodies IgG and IgM, detection of HLA genotype of A
locus, using sequence specific PCR and LIPA, and screening
for CMV infection by monitoring of pp65 antigenemia using
the immunofluorescence technique.
Results of the present study showed that all patients (no.
= 30) were seropositive (CMV IgG positive) with seronega-
tive donors. Nine patients (30%) were positive for CMVpp65
antigenemia. Anti-CMV IgM was positive in 2 out of 9
CMVpp65 positive patients (22.2%). Among CMVpp65 anti-
genemia positive patients (no. = 9), 4 patients (44.4%)
showed symptoms of CMV disease in the form of fever,
pneumonia and leukopenia. The number of CMVpp65-
positive cells was between 1 and 5 cells per 2  106 PBL
among the 9 CMVpp65 positive samples. The detected
HLA-A alleles were HLA-A*01(no. = 16), HLA-A*02(no.
= 11), HLA-A*11(no. = 5), HLA-A*19(no. = 1), HLA-
A*24(no. = 4), HLA-A*29(no. = 1), HLA-A*30(no. = 16)
and HLA-A*92(no. = 4). HLA-A*1–30 type represented
40% of the studied cases. There was a significant difference
among detected HLA types as regards CMVpp65 antigene-
mia, where the majority of CMVpp65 positive patients
(33.3%) belonged to the HLA-A*02_11 type (compared to
11.1% among each of the other HLA types) and the majority
of CMVpp65 negative patients (57.1%) belonged to the
HLA-A*01_30 type Also, there was a significant association
between CMVpp65 antigenemia and CMV disease. However,
no statistically significant relation was found between HLA
types versus CMV disease.Similarly in the study of Fan et al. [11] liver transplantation
recipients were serum CMV IgG positive (100%). Thirty-three
recipients (84.6%) were CMV antigenic positive with average
of 7.2 ± 4.2 positive leukocytes per 50,000 leukocytes on. Thir-
teen patients developed CMV pneumonia, with CMV antigenic
positive (100%). They concluded that some HLA alleles were
associated with the occurrence and extent of CMV antigenemia.
However, their results demonstrated that HLA-A2 was the
higher frequency allele for patients with antigenemia
(P< 0.05). In the lower antigenemia group, HLA-A11 was
higher in frequency than others (P< 0.05). Besides, none of
the patients carrying HLA-B16 allele developed clinical symp-
toms of CMV infection (P< 0.05). They failed to detect anti-
CMV IgM among patients with CMV disease. It was explained
by the immunosuppression condition of recipients.
The study of Kekik et al. [17] included 108 patients who
received an allogeneic stem cell graft from an HLA-identical
sibling between 1993 and 2004. All recipients and donors were
typed for HLA-A, HLA-B, and HLA-DR alleles using sero-
logic or molecular methods. In contrary to the results of the
present study, seropositive patients with post-transplantation
CMV infection demonstrated a higher incidence of HLA-
A30, HLA-B40, and HLA-DRB1*15 compared with those
without CMV infection. This difference may be attributed to
difference in sample size.
Also Varga [6] reported that genetic variability influences
susceptibility to infectious diseases and HLA-molecules are
critical for viral antigen up-taking, processing and presenting.
352 R. Khalifa et al.They studied 129 of high-risk patients and suggested that
recipients positive for HLA-DQ3 are more susceptible to
CMV-infection than a comparable group of patients negative
for this HLA-type.
Thus, the variability of HLA alleles might modulate
immune response to CMV infection. HLA examination before
transplantation should be made for prevention and treatment
of CMV infection after operation [11].
9. Conclusions and recommendations
Certain HLA alleles may have either a protective or a predis-
posing role in CMV reactivation. Thus, HLA typing might be
helpful in estimating the risk of CMV disease during the post-
transplantation period and designing individualized therapy as
regards the choice between preemptive and prophylactic CMV
therapy. Further studies including other HLA loci genotypes
are recommended to clarify the role of other HLA types in
the susceptibility of solid-organ transplantation patients to
CMV infection.
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